| 1. | Bock, PR, Hanisch, J, Hoffmann, J, Dierdorf, RE, Werner, M, Schürholz, T, Schneider, B, and IFAG Basel: Efficacy and safety of the standardized mistletoe extract (iscador) in the postsurgical therapy of patients with primary carcinoma: a multicenter, retrolective cohort study according to good epidemiological practice (GEP) guidelines. 2002; 25. Dtsch. Krebskongress, Berlin [Abstr.No. A860]. |
| 2. | Edler L: Chemotherapie mit komplementärer Misteltherapie: wie evident ist ihre Wirksamkeit wirklich? internist. praxis 2003; 43: 895–904. |
| 3. | Eggermont, AMM, Kleeberg, UR, Ruiter, DJ, and Suciu, S: European Organization for Research and Treatment of Cancer Melanoma Group. Trial experience with more than 2,000 patients, evaluating adjuvant treatment with low or intermediate doses of interferon alpha-2b. In: Perry, M C: American Society of Clinical Oncology. Educational Book, 2001; 37th Annual Meeting. Alexandria, VA, USA, 88–93. |
| 4. | Feinstein AR: Clinical Epidemiology. Philadelphia: Saunders 1985. |
| 5. | Fox BH: Quandaries created by unlikely numbers in some of Grossarth-Maticek's studies. Psychol Inquiry 1991; 2: 242–247. |
| 6. | Grossarth-Maticek R, Kiene H, Baumgartner SM, Ziegler R: Use of iscador, an extract of European mistletoe (viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Alternat Ther Hlth Med 2001; 7: 57–78. (Übersetzung ins Deutsche 2002 vertrieben durch Weleda AG Schwäbisch Gmünd, Art. Nr. 50 605 900). MEDLINE |
| 7. | Hartenstein R: Anthroposophische Krebstherapie: Klinische Forschung. Akt Onkol 1985; 32: 216–222. |
| 8. | Hauser SP: Unproven methods in cancer treatment. Curr Opin Oncol 1993; 5: 646–654. MEDLINE |
| 9. | Heiny BM, Albrecht V: Mistellektine beim fortgeschrittenen kolorektalen Karzinom. Kassenarzt 1998; 38: 41–44. |
| 10. | Hiller, B: Unkonventionelle Verfahren in der Onkologie: Der Informationsbedarf der Anrufer beim Krebsinformationsdienst im Deutschen Krebsforschungszentrum zu Methoden mit bisher unbewiesener Wirksamkeit. Medizinische Fakultät Universität Heidelberg, Dissertation 2001. |
| 11. | Kiene H: Klinische Studien zur Misteltherapie karzinomatöser Erkrankungen: eine Übersicht. Therapeutikon 1989; 3: 347–353. |
| 12. | Kleijnen J, Knipschild P: Mistletoe treatment for cancer. Review of controlled trials in humans. Phytomed 1994; 1: 255–260. |
| 13. | Lenartz D, Dott U, Menzel J, Schürholz JM, Beuth J: Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res 2000; 20: 2073–2076. MEDLINE |
| 14. | Nagel GA, Schmähl D: Krebsmedikamente mit fraglicher Wirksamkeit. Akt Onkol 1984; 11–49. |
| 15. | Pampallona S, von Rohr E, von Wegberg B, Bernhard J, Helwig S, Heusser P, Hürny C, Schaad R, Cerny T: Socio-demographic and medical characteristics of advanced cancer patients using conventional or complementary medicine. Onkol 2002; 25: 165–170. MEDLINE |
| 16. | Schneider B, Bock PR: Epidemiologische Kohortenstudien. Schweiz Ztschr GanzheitsMed 2002; 13: 400–403. |
| 17. | Schumacher K, Schneider B, Reich G, Stiefel T, Stoll G, Bock PR, Hanisch J, Beuth J: Postoperative komplementäre Therapie des primären Mammakarzinoms mit lektinnormiertem Mistelextrakt. Eine epidemiologische, kontrollierte, multizentrische retrolektive Kohortenstudie. biosyn 2002; 10–22. |
| 18. | Stauder H, Kreuser ED: Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research. Onkol 2002; 25: 374–380. MEDLINE |
| 19. | Steuer-Vogt MK, Bonkowsky V, Ambrosch P, Scholz M, Neiß A, Strutz J, Henning M, Lenarz T, Arnold W: The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer 2001; 37: 23–31. MEDLINE |
| 20. | van der Ploeg HM: What a wonderful world it would be: a reanalysis of some of the work of Grossarth-Maticek. Psychol Inquiry 1991; 2: 280–285. |
| 21. | Wetzel, D and Schäfer, M: Results of a randomised placebo-controlled multicentre study with PS76A2 (standardised mistletoe preparation) in patients with breast cancer receiving adjuvant chemotherapy. International Congrress of Phytomedicine [Abstr.No. SL-66]. München, October 2000. |
| 22. | Winship C, Morgan SL: The estimation of causal effects from observational data. Ann Rev Sociol 1999; 25: 659–707. |